Featured Research

from universities, journals, and other organizations

New drug therapy for CLL under examination

Date:
March 19, 2014
Source:
North Shore-Long Island Jewish (LIJ) Health System
Summary:
Two American physicians weigh in on a German study of a new drug therapy for CLL. CLL is one of the most common forms of blood cancers, usually affecting those later in life. In the editorial, they point out that an important factor in the study is that most of the nearly 800 subjects are elderly with coexisting other health issues.

Two North Shore-LIJ Cancer Institute doctors, world-renowned for their research in chronic lymphocytic leukemia (CLL), weigh in on a German study of a new drug therapy for CLL in the March 20 edition of the New England Journal of Medicine, the North Shore-LIJ Health System announced today.

Related Articles


CLL is one of the most common forms of blood cancers, usually affecting those later in life. In an editorial written by Kanti Rai, MD, chief of CLL Research and Treatment Program for the health system, and Jacqueline Barrientos, MD, a research hematologist on staff at the CLL Program, they point out that an important factor in the study is that most of the nearly 800 subjects are elderly with coexisting other health issues.

Until now, researchers have skipped this population in favor of younger and healthier subjects, say the doctors, who also have academic appointments at Hofstra North Shore-LIJ School of Medicine. However, the average age of CLL patients at diagnosis is 72, and most usually have other health problems.

The study focused on the use of obinutuzumab, an antibody that binds to the protein CD20, in subjects with previously untreated CLL and coexisting conditions. Most cases of CLL start in white blood cells that have CD20 on their surface.

Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had an average of 26.7 months progression-free of the disorder compared to 16.3 for those given rituximab-chlorambucil. To read more about the study, visit the New England Journal of Medicine online.

Findings of the study will have an important impact on future CLL research, explained Dr. Rai, who is also an investigator at North Shore-LIJ's Feinstein Institute for Medical Research. "The researchers' work will encourage future use of obinutuzumab in combination with other drugs and help shape the clinical landscape of CLL in the next decade."


Story Source:

The above story is based on materials provided by North Shore-Long Island Jewish (LIJ) Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kanti R. Rai, Jacqueline C. Barrientos. Movement toward Optimization of CLL Therapy. New England Journal of Medicine, 2014; 370 (12): 1160 DOI: 10.1056/NEJMe1400599

Cite This Page:

North Shore-Long Island Jewish (LIJ) Health System. "New drug therapy for CLL under examination." ScienceDaily. ScienceDaily, 19 March 2014. <www.sciencedaily.com/releases/2014/03/140319195857.htm>.
North Shore-Long Island Jewish (LIJ) Health System. (2014, March 19). New drug therapy for CLL under examination. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/03/140319195857.htm
North Shore-Long Island Jewish (LIJ) Health System. "New drug therapy for CLL under examination." ScienceDaily. www.sciencedaily.com/releases/2014/03/140319195857.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins